Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
Sheng‐Nan Lu, Jing‐Houng Wang, Chien‐Wei Su, et al.
Journal of the Formosan Medical Association (2017) Vol. 117, Iss. 5, pp. 381-403
Open Access | Times Cited: 111

Showing 1-25 of 111 citing articles:

Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma
Ann‐Lii Cheng, Chiun Hsu, Stephen L. Chan, et al.
Journal of Hepatology (2020) Vol. 72, Iss. 2, pp. 307-319
Open Access | Times Cited: 434
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS–ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO
L.-T. Chen, Erika Martinelli, Ann‐Lii Cheng, et al.
Annals of Oncology (2020) Vol. 31, Iss. 3, pp. 334-351
Open Access | Times Cited: 191
Breakthroughs in Hepatocellular Carcinoma Therapies
Amit G. Singal, Masatoshi Kudo, Jordi Bruix
Clinical Gastroenterology and Hepatology (2023) Vol. 21, Iss. 8, pp. 2135-2149
Open Access | Times Cited: 81
A New Treatment Option for Intermediate-Stage Hepatocellular Carcinoma with High Tumor Burden: Initial Lenvatinib Therapy with Subsequent Selective TACE
Masatoshi Kudo
Liver Cancer (2019) Vol. 8, Iss. 5, pp. 299-311
Open Access | Times Cited: 125
Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
Yu‐Yun Shao, Shen-Yung Wang, Shi‐Ming Lin, et al.
Journal of the Formosan Medical Association (2020) Vol. 120, Iss. 4, pp. 1051-1060
Open Access | Times Cited: 99
Propofol-based total intravenous anaesthesia is associated with better survival than desflurane anaesthesia in hepatectomy for hepatocellular carcinoma: a retrospective cohort study
Hou‐Chuan Lai, Meei‐Shyuan Lee, Chin Lin, et al.
British Journal of Anaesthesia (2019) Vol. 123, Iss. 2, pp. 151-160
Open Access | Times Cited: 84
Portal Vein Tumor Thrombosis and Hepatocellular Carcinoma – The Changing Tides
Abdul Rehman Khan, Xuyong Wei, Xiao Xu
Journal of Hepatocellular Carcinoma (2021) Vol. Volume 8, pp. 1089-1115
Open Access | Times Cited: 77
Artificial intelligence in precision medicine in hepatology
Tung‐Hung Su, Chih‐Horng Wu, Jia‐Horng Kao
Journal of Gastroenterology and Hepatology (2021) Vol. 36, Iss. 3, pp. 569-580
Open Access | Times Cited: 63
The Role of IGF/IGF-1R Signaling in Hepatocellular Carcinomas: Stemness-Related Properties and Drug Resistance
Mai-Huong Thi Ngo, Han-Yin Jeng, Yung‐Che Kuo, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 4, pp. 1931-1931
Open Access | Times Cited: 58
Overview of Asian clinical practice guidelines for the management of hepatocellular carcinoma: An Asian perspective comparison
Yuri Cho, Bo Hyun Kim, Joong‐Won Park
Clinical and Molecular Hepatology (2023) Vol. 29, Iss. 2, pp. 252-262
Open Access | Times Cited: 41
Arterial chemotherapy for hepatocellular carcinoma in China: consensus recommendations
Ming Zhao, Zhi Guo, Yinghua Zou, et al.
Hepatology International (2023) Vol. 18, Iss. 1, pp. 4-31
Closed Access | Times Cited: 26
Correlation and efficacy of TACE combined with lenvatinib plus PD‐1 inhibitor in the treatment of hepatocellular carcinoma with portal vein tumor thrombus based on immunological features
Xinhua Zou, Qingyu Xu, Ran You, et al.
Cancer Medicine (2023) Vol. 12, Iss. 10, pp. 11315-11333
Open Access | Times Cited: 24
Clinical Manifestations and Outcomes of Patients with Sarcomatoid Hepatocellular Carcinoma
Sih‐Han Liao, Tung‐Hung Su, Yung‐Ming Jeng, et al.
Hepatology (2018) Vol. 69, Iss. 1, pp. 209-221
Closed Access | Times Cited: 67
New treatment paradigm with systemic therapy in intermediate-stage hepatocellular carcinoma
Masatoshi Kudo
International Journal of Clinical Oncology (2022) Vol. 27, Iss. 7, pp. 1110-1119
Open Access | Times Cited: 32
H1-Antihistamines Reduce the Risk of Hepatocellular Carcinoma in Patients With Hepatitis B Virus, Hepatitis C Virus, or Dual Hepatitis B Virus-Hepatitis C Virus Infection
Yu-Chuan Shen, Hui‐Ching Hsu, Tzu‐Min Lin, et al.
Journal of Clinical Oncology (2022) Vol. 40, Iss. 11, pp. 1206-1219
Open Access | Times Cited: 29
Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Taiwan perspective
Tung‐Hung Su, Chih‐Horng Wu, Tsung‐Hao Liu, et al.
Clinical and Molecular Hepatology (2023) Vol. 29, Iss. 2, pp. 230-241
Open Access | Times Cited: 21
Real-World Data on the Diagnosis, Treatment, and Management of Hepatocellular Carcinoma in the Asia-Pacific: The INSIGHT Study
Yu Ki Sim, Ming Chuen Chong, Mihir Gandhi, et al.
Liver Cancer (2023) Vol. 13, Iss. 3, pp. 306-321
Open Access | Times Cited: 18
Review article: the prevention of hepatitis B-related hepatocellular carcinoma
Cheng‐Li Lin, Jia‐Horng Kao
Alimentary Pharmacology & Therapeutics (2018) Vol. 48, Iss. 1, pp. 5-14
Open Access | Times Cited: 54
Characteristics and etiologies of hepatocellular carcinoma in patients without cirrhosis: When East meets West
Yi‐Hao Yen, Yu‐Fan Cheng, Jing‐Houng Wang, et al.
PLoS ONE (2021) Vol. 16, Iss. 1, pp. e0244939-e0244939
Open Access | Times Cited: 33
Adjuvant and neoadjuvant therapies for hepatocellular carcinoma
Arndt Vogel, Robert C. Grant, Tim Meyer, et al.
Hepatology (2023)
Closed Access | Times Cited: 14
Paradigm shift in the treatment options of hepatocellular carcinoma
Tung‐Hung Su, Shih‐Jer Hsu, Jia‐Horng Kao
Liver International (2021) Vol. 42, Iss. 9, pp. 2067-2079
Open Access | Times Cited: 31
Role of modern radiotherapy in managing patients with hepatocellular carcinoma
Liang‐Cheng Chen, Hon‐Yi Lin, Shih‐Kai Hung, et al.
World Journal of Gastroenterology (2021) Vol. 27, Iss. 20, pp. 2434-2457
Open Access | Times Cited: 29
Entecavir versus tenofovir on prognosis of hepatitis B virus‐related hepatocellular carcinoma after curative hepatectomy
Wei‐Yu Kao, Elise Chia‐Hui Tan, Hsin‐Lun Lee, et al.
Alimentary Pharmacology & Therapeutics (2023) Vol. 57, Iss. 11, pp. 1299-1312
Closed Access | Times Cited: 12
Surveillance, Diagnosis, and Treatment Outcome of Hepatocellular Carcinoma in Japan: 2023 Update
Masatoshi Kudo
Liver Cancer (2023) Vol. 12, Iss. 2, pp. 95-102
Open Access | Times Cited: 11
A novel surgical scheme for hepatectomy in hepatocellular carcinoma patients with clinically significant portal hypertension
Jiazhou Ye, Hua-ze Lu, Can Zeng, et al.
BMC Cancer (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top